Homegrown biotechnology startup Cambrian Bioworks has raised $1.45 million (approx. Rs 12 crore) in a seed funding round led by the Irani family office, along with participation from the firm’s cofounder and CEO Vaibhav Hegde.
The company intends to use the fresh funding to scale up its automated molecular diagnostics platforms, bolster R&D efforts, expand team and support international market expansion, reports Inc42.
“Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey,” said Hegde.
The company was founded in 2020, by Hegde, Rohit Asil and Raghav Sridhar. It builds automated molecular diagnostic platforms.
The company’s products are used in oncology, genomics, rare disease testing, and AMR detection. The company manufactures tools for the molecular diagnostics and advanced DNA sequencing markets.
It recently launched Manta, a nucleic acid extraction platform that provides high-quality DNA and RNA for genomics and PCR testing in hospitals and laboratories.